Development of [89Zr]Zr-DFO-hu3F8 and [225Ac]Ac-DOTA-hu3F8 Theranostic Pairs Targeting GD2 in Neuroblastomas
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c02837 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Lingling Zheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing 100050, China. Hauptthemen laut MEDLINE: Zirconium, Neuroblastoma, Radiopharmaceuticals, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Natural Science Foundation of Beijing Municipality, National Natural Science Foundation of China.
Abstract (Originalsprache)
Relapsed and refractory high-risk neuroblastoma (NBL) patients have limited treatment options and a poor prognosis, highlighting the urgent need for novel targeted therapies. This study evaluates the GD2-targeting PET imaging agent [89Zr]Zr-DFO-hu3F8 and the radioimmunotherapy agent [225Ac]Ac-DOTA-hu3F8 in NBL animal models. The GD2 overexpressing IMR32 tumor was assessed by using [89Zr]Zr-DFO-hu3F8 PET imaging to confirm targeting efficacy. The safety and therapeutic efficacy of [225Ac]Ac-DOTA-hu3F8 were evaluated in GD2-positive NBL xenografts. ImmunoPET revealed the high and sustained uptake of [89Zr]Zr-DFO-hu3F8 in IMR32 tumors compared to the [89Zr]Zr-DFO-IgG control group. In vitro biodistribution analysis showed that a tumor uptake was 58.47 ± 3.64%ID/g at 168 h post-injection. A single dose of [225Ac]Ac-DOTA-hu3F8 treatment significantly suppressed tumor growth, with most tumors (4/5) achieving complete remission at medium and high doses (11.1 and 18.5 kBq). Overall, our findings demonstrate that alpha-targeted therapy based on hu3F8 holds significant potential as a promising curative treatment strategy for NBL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing 100050, China.
- Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
ORCID-Profile: Lingling Zheng, Guanyun Wang, Jianhua Gong
Förderung
- Natural Science Foundation of Beijing Municipality
- National Natural Science Foundation of China
Zitieren
APA
Zheng, L., Yang, X., Liu, J., Wang, G., Zhou, Z. A., Xu, Y., Gong, J., & Yang, J. (2025). Development of [89Zr]Zr-DFO-hu3F8 and [225Ac]Ac-DOTA-hu3F8 Theranostic Pairs Targeting GD2 in Neuroblastomas. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02837
Vancouver
Zheng L, Yang X, Liu J, Wang G, Zhou ZA, Xu Y, et al. Development of [89Zr]Zr-DFO-hu3F8 and [225Ac]Ac-DOTA-hu3F8 Theranostic Pairs Targeting GD2 in Neuroblastomas. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c02837
BibTeX
@article{Zheng2025,
author = {Zheng, Lingling and Yang, Xu and Liu, Jun and Wang, Guanyun and Zhou, Zi Ang and Xu, Yanfeng and Gong, Jianhua and Yang, Jigang},
title = {Development of [89Zr]Zr-DFO-hu3F8 and [225Ac]Ac-DOTA-hu3F8 Theranostic Pairs Targeting GD2 in Neuroblastomas},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c02837}
}
EUVIMED